Scilex, a subsidiary of Sorrento Therapeutics, has entered into a merger agreement with SPAC Vickers Vantage Corp. I. In the escrow account of Vickers now has $140 million. Scilex shareholders will own 88% of the combined company, which will be called Scilex Holding Company, and its stock and warrants will trade on Nasdaq under the tickers SCLX and SCLXW. The merger is expected to be completed in the third quarter of 2022.